This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioProcess International: COVID-19 Therapeutic Development & Production
April 27-28, 2021
Delivered in a 100% Virtual FormatBritish Summer Time (BST)

Robert Gronke, PhD
Senior Principal Scientist, Technical Development at Biogen, Inc


Robert Gronke is a Senior Principal Scientist in the Technical Department at Biogen, Inc.  For the past 27 years, he’s been involved in the purification development, CMC team leadership, regulatory liaison and new technology assessment for recombinant biopharmaceuticals including Biogen’s commercial products AVONEX (Interferon Beta-1a), a serum-free version of AVONEX, PLEGRIDY (PEG IFN Beta-1a), BENEPALI (Enbrel biosimilar), SPINRAZA (SMA antisense oligonucleotide), APROLIX (Factor IX-Fc), and AMEVIVE (glycosylated fusion protein), along with clinical products including αVβ6, αVβ5, anti-Tau and anti-BDCA monoclonal antibodies, antisense oligonucleotides (SOD-1) and several others.  Rob currently manages a group of 4 associate scientists.

Prior to joining Biogen, Inc., Dr. Gronke was a post-doctoral fellow in the Pharmacology Department at Merck Sharp & Dohme Research Laboratories in West Point, Pennsylvania (1988 – 1989).  He received his Ph.D. degree in Biochemistry from the University of Kansas, Lawrence Kansas in 1987.  Prior to receiving his Ph.D., he was employed as a Research Associate at the University of Illinois, Chicago (1982 – 1983).  Dr. Gronke received a BS degree in Biochemistry from Northern Illinois University, DeKalb, Illinois in 1982.

Agenda Sessions

  • Assessment of IFN Beta Therapies as Potential Treatments for COVID-19